75 related articles for article (PubMed ID: 32955091)
1. Circulating tumor DNA is a sensitive marker for routine monitoring of treatment response in advanced colorectal cancer.
Zou D; Day R; Cocadiz JA; Parackal S; Mitchell W; Black MA; Lawrence B; Fitzgerald S; Print C; Jackson C; Guilford P
Carcinogenesis; 2020 Nov; 41(11):1507-1517. PubMed ID: 32955091
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients.
Yang YC; Wang D; Jin L; Yao HW; Zhang JH; Wang J; Zhao XM; Shen CY; Chen W; Wang XL; Shi R; Chen SY; Zhang ZT
Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29914973
[TBL] [Abstract][Full Text] [Related]
3. The Importance of Feasibility Assessment in the Design of ctDNA Guided Trials - Results From the OPTIPAL II Study.
Callesen LB; Boysen AK; Andersen CSA; Pallisgaard N; Spindler KG
Clin Colorectal Cancer; 2023 Dec; 22(4):421-430.e1. PubMed ID: 37586928
[TBL] [Abstract][Full Text] [Related]
4. Rational thresholding of circulating tumor DNA concentration for improved surveillance of metastatic breast cancer.
Martens GA; Demol J; Dedeurwaerdere F; Breyne J; De Smet K; De Jaeger P; De Smet D
ESMO Open; 2024 Feb; 9(2):102235. PubMed ID: 38320429
[TBL] [Abstract][Full Text] [Related]
5. Role of Circulating Tumor DNA Among Patients with Colorectal Peritoneal Metastases.
Baumgartner JM; Botta GP
J Gastrointest Cancer; 2024 Mar; 55(1):41-46. PubMed ID: 37436640
[TBL] [Abstract][Full Text] [Related]
6. BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer.
Kasi PM; Sawyer S; Guilford J; Munro M; Ellers S; Wulff J; Hook N; Krinshpun S; Koyen Malashevich A; Malhotra M; Rodriguez A; Moshkevich S; Grothey A; Kopetz S; Billings P; Aleshin A
BMJ Open; 2021 Sep; 11(9):e047831. PubMed ID: 34561256
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity of a blood ctDNA-based multimodal test for the detection of advanced colorectal neoplasms.
Brenner H; Niedermaier T; Hoffmeister M
Ann Oncol; 2024 May; 35(5):476-477. PubMed ID: 38311210
[No Abstract] [Full Text] [Related]
8. Circulating Tumor DNA in Colorectal Cancer Liver Metastasis: Analysis of Patients Receiving Liver Resection and Transplant.
Wehrle CJ; Raj R; Aykun N; Orabi D; Stackhouse K; Chang J; Estfan B; Kamath S; Krishnamurthi S; Walsh RM; Kwon DCH; Aucejo F
JCO Clin Cancer Inform; 2023 Sep; 7():e2300111. PubMed ID: 37820293
[TBL] [Abstract][Full Text] [Related]
9. Patient specific circulating tumor DNA fingerprints to monitor treatment response across multiple tumors.
Li J; Jiang W; Wei J; Zhang J; Cai L; Luo M; Wang Z; Sun W; Wang S; Wang C; Dai C; Liu J; Wang G; Wang J; Xu Q; Deng Y
J Transl Med; 2020 Aug; 18(1):293. PubMed ID: 32738923
[TBL] [Abstract][Full Text] [Related]
10. The utilization of circulating tumor DNA to predict the risk and location of relapse after curative-intent local therapy in oligometastatic colorectal cancer.
Radomski SN; Ali S; Lafaro KJ; Shubert C; Hidalgo M; Chung H; Christenson ES
J Gastrointest Surg; 2024 Apr; 28(4):534-537. PubMed ID: 38583907
[No Abstract] [Full Text] [Related]
11. Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer.
Patelli G; Mauri G; Tosi F; Amatu A; Bencardino K; Bonazzina E; Pizzutilo EG; Villa F; Calvanese G; Agostara AG; Stabile S; Ghezzi S; Crisafulli G; Di Nicolantonio F; Marsoni S; Bardelli A; Siena S; Sartore-Bianchi A
Clin Cancer Res; 2023 Nov; 29(22):4530-4539. PubMed ID: 37436743
[TBL] [Abstract][Full Text] [Related]
12. Levels of circulating tumor DNA correlate with tumor volume in gastro-intestinal stromal tumors: an exploratory long-term follow-up study.
Bleckman RF; Haag CMSC; Rifaela N; Beukema G; Mathijssen RHJ; Steeghs N; Gelderblom H; Desar IME; Cleven A; Ter Elst A; Schuuring E; Reyners AKL
Mol Oncol; 2024 May; ():. PubMed ID: 38790141
[TBL] [Abstract][Full Text] [Related]
13. On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer.
Moser T; Waldispuehl-Geigl J; Belic J; Weber S; Zhou Q; Hasenleithner SO; Graf R; Terzic JA; Posch F; Sill H; Lax S; Kashofer K; Hoefler G; Schoellnast H; Heitzer E; Geigl JB; Bauernhofer T; Speicher MR
NPJ Precis Oncol; 2020 Nov; 4(1):30. PubMed ID: 33299124
[TBL] [Abstract][Full Text] [Related]
14. Undetectable
Bouchahda M; Saffroy R; Karaboué A; Hamelin J; Innominato P; Saliba F; Lévi F; Bosselut N; Lemoine A
JCO Precis Oncol; 2020; 4():. PubMed ID: 33015528
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer.
van 't Erve I; Greuter MJE; Bolhuis K; Vessies DCL; Leal A; Vink GR; van den Broek D; Velculescu VE; Punt CJA; Meijer GA; Coupé VMH; Fijneman RJA
J Mol Diagn; 2020 Dec; 22(12):1430-1437. PubMed ID: 32961317
[TBL] [Abstract][Full Text] [Related]
16. Serial Circulating Tumor DNA in Predicting and Monitoring the Effect of Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer: A Prospective Multicenter Study.
Zhou J; Wang C; Lin G; Xiao Y; Jia W; Xiao G; Liu Q; Wu B; Wu A; Qiu H; Zhang F; Hu K; Xue H; Shen Z; Wang Z; Han J; Niu B; Xu Y; Yu Z; Yang L
Clin Cancer Res; 2021 Jan; 27(1):301-310. PubMed ID: 33046514
[TBL] [Abstract][Full Text] [Related]
17. Treatment monitoring of colorectal cancer by integrated analysis of plasma concentration and sequencing of circulating tumor DNA.
Yeh YM; Lin PC; Lee CT; Chen SH; Lin BW; Lin SC; Chen PC; Chan RH; Shen MR
Mol Cancer; 2020 Oct; 19(1):150. PubMed ID: 33106181
[TBL] [Abstract][Full Text] [Related]
18. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients.
Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T
BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758
[TBL] [Abstract][Full Text] [Related]
19. Circulating Tumor DNA as a Biomarker for Outcomes Prediction in Colorectal Cancer Patients.
Petrillo A; Salati M; Trapani D; Ghidini M
Curr Drug Targets; 2021; 22(9):1010-1020. PubMed ID: 33155906
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]